Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

Autores
Categoría Estudio primario
Registro de estudiosClinicalTrials.gov
Año 23
Inclusion in the study must occur ≥4 but \<10 weeks after the date of last dose of first-line chemotherapy. Post-chemotherapy confirmatory scan(s) for eligibility must be performed within 28 days prior to inclusion in the study to assess response status following first-line chemotherapy. Patients with ongoing partial response (PR) or stable disease (SD) (per RECIST v1.1) and who have measurable disease (per RECIST v1.1) are eligible for the study.
Epistemonikos ID: 778d189d7fe66e38a5b91983fb04560b1d2e3dd8
First added on: Oct 02, 2023